Clinical Trials Directory

Trials / Completed

CompletedNCT00038636

A Study of Two Different Doses of ABT-378/Ritonavir in HIV-Infected Patients Who Have Taken Protease Inhibitors and Non-Nucleoside Reverse Transcriptase Inhibitors

Status
Completed
Phase
Phase 3
Study type
Interventional
Enrollment
36 (planned)
Sponsor
Abbott · Industry
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to determine the safety and effectiveness of a high dose of ABT-378/ritonavir

Conditions

Interventions

TypeNameDescription
DRUGLopinavir/ritonavir
DRUGRitonavir

Timeline

Start date
2000-09-01
First posted
2002-06-04
Last updated
2006-08-15

Locations

7 sites across 3 countries: United States, France, Spain

Source: ClinicalTrials.gov record NCT00038636. Inclusion in this directory is not an endorsement.

A Study of Two Different Doses of ABT-378/Ritonavir in HIV-Infected Patients Who Have Taken Protease Inhibitors and Non- (NCT00038636) · Clinical Trials Directory